Hemodynamic Effects of Variations in Net Ultrafiltration Rate During Continuous Renal Replacement Therapy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-06

Study Completion Date

2025-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Net ultra filtration (NUF) is one of the most important parameters during renal replacement therapy (RRT) whose role is to control fluid balance by water removal.

To our knowledge, there are no prospective studies or guidelines about the setting of this parameter.

In the NEPTUNE study, we aim to compare the hemodynamic effect of three NUF rates during RRT: 1 ml/kg/h, 2 ml/kg/h and 3 ml/kg/h.

The research hypothesis is that one of the three flow rates evaluated induces the fewest hemodynamic instabilities related to RRT, while guaranteeing the best possible fluid balance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure

NCT05817539

Acute Kidney Injury Fluid Overload

RECRUITING NA

A Net Ultrafiltration Challenge to Predict Preload-dependence (UF CHALLENGE)

NCT05214729

Acute Kidney Injury

COMPLETED NA

The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care

NCT01403220

Renal Failure, Acute

COMPLETED NA

Effect of the Intensity of Continuous Renal Replacement Therapy

NCT01251081

Optimal Intensity of Renal Replacement Therapy on Sepsis Patients

COMPLETED NA

Effect of Citrate on the Coagulation System in Patients Receiving CRRT

NCT02486614

Acute Kidney Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Renal renal replacement therapy (RRT) for severe acute kidney injury is one of the most widely used life-support techniques in intensive care. One of its main functions is to maintain the water balance in oligo-anuric patients by means of net ultrafiltration (NUF), defined as the volume of water removed from the patient by the RRT per unit time and indexed to the patient's weight.

Surprisingly, the setting of this parameter, which is one of the most important, there are no guidelines. If net ultrafiltration is too low, it may prolong RRT dependency and length of stay in the ICU, with all the associated care-related complications, and increase mortality. If net ultrafiltration is too high, it may transiently induce hypovolemia, leading to hemodynamic instability related to renal replacement therapy (HIRRT).

A recent survey of French practices shows that the average NUF flow rate used in intensive care units in France is 119 ± 77 ml/h, and the median flow rate is 100 ml/h \[min-max 20-300\]; in this study, NUF was not indexed by weight, but for a patient with an average weight of 75 kg, corresponding to an average NUF of 1.6 ± 1 ml/kg/h.

In the NEPTUNE study, the investigators aim to compare the hemodynamic effect of three net ultrafiltration rates during RRT: 1 ml/kg/h, 2 ml/kg/h and 3 ml/kg/h. These three flow rates are within the range of those usually used in clinical practice.The research hypothesis is that one of the three flow rates evaluated induces the fewest hemodynamic instabilities related to RRT, while guaranteeing the best possible fluid balance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fluid Overload Hemodynamic Instability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Multiple N of one trial

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 ml/kg/h

Net ultra filtration setting: 1 ml/kg/h

Group Type EXPERIMENTAL

Net Ultra Filtration Rate

Intervention Type DEVICE

The net ultra filtration rate is modified every 6 hours accordingly to randomisation

2 ml/kg/h

Net ultra filtration setting: 2 ml/kg/h

Group Type EXPERIMENTAL

Net Ultra Filtration Rate

Intervention Type DEVICE

The net ultra filtration rate is modified every 6 hours accordingly to randomisation

3 ml/kg/h

Net ultra filtration setting: 3 ml/kg/h

Group Type EXPERIMENTAL

Net Ultra Filtration Rate

Intervention Type DEVICE

The net ultra filtration rate is modified every 6 hours accordingly to randomisation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Net Ultra Filtration Rate

The net ultra filtration rate is modified every 6 hours accordingly to randomisation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalised in the intensive care unit of one of the two participating centres
* Patients with Kidney Disease: Improving Global Outcomes 3 (KDIGO3) acute kidney injury (AKI) requiring a continuous RRT during their stay in the intensive care unit, regardless of the aetiology of the AKI
* Need to prescribe water loss by net ultrafiltration (NUF), defined by at least one of the following sub-criteria:

1. weight gain ≥ 1 kg relative to entry weight
2. oligo-anuria ≥ 24 hours
3. clinical impact of fluid overload as judged by the clinician: acute lung oedema clinical or at CT-scan, difficulty of weaning from mechanical ventilation.
* Hemodynamic stability in the 2 hours preceding the start of NUF, defined by all of the following sub-criteria:

1. absence of vasopressors (noradrenaline) or stability or reduction in their dosage
2. no need for resuscitative fluids as judged by the clinician
* Patient or his/her trusted support person/legal representative/family member having given free and informed consent, and having signed the consent form or patient included in an emergency situation.
* Patient affiliated to or benefiting from a health insurance scheme.

Exclusion Criteria

* Patient moribund, with life expectancy too low to benefit from treatment, or with decision to discontinue treatment
* Patient participating in an another interventional study
* Patient in exclusion period determined by another study
* Patient under court protection or guardianship
* Patient/trusted person/legal representative/family member for whom it is impossible to give informed information.
* Pregnant, parturient or breast-feeding patient.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No